(Q44599587)

4 December 2017

1 reference

title

Value of anti-TNF-alpha molecules in inflammatory and infectious diseases (English)

1 reference

4 December 2017

0 references

B Fautrel

1

1 reference

4 December 2017

P Cherin

series ordinal

2

1 reference

4 December 2017

language of work or name

French

0 references

publication date

1 October 2000

1 reference

Revue de Médecine Interne

4 December 2017

published in

1 reference

4 December 2017

volume

21

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

872-888

1 reference

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

How important are T cells in chronic rheumatoid synovitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Anticytokine Therapy in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Biological agents in rheumatoid arthritis: which ones could be used in combination?

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Biologic agents in the treatment of inflammatory rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Th1/Th2 cytokine balance in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Biological insights from clinical trials with anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Biologic agents for treating rheumatoid arthritis. Concepts and progress

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

[Therapy of refractory chronic polyarthritis with tumor necrosis factor alpha receptor fusion protein (TNFR55-IgG1)--long term follow-up of 80 personal cases]

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

Therapeutic antibodies elicited by immunization against TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2800%2900238-1

7 January 2021

10.1016/S0248-8663(00)00238-1

Identifiers

DOI

1 reference

4 December 2017

1 reference